. Indeed, crystallographic analysis of the Vi and V2 domain structure has revealed that Vi and V2 are very closely packed with a beta strand that passes continuously from one domain to another (20, 25) . In contrast, the critical CD4-binding site(s) on gpi20 is not well characterized. Several studies indicate that this site may encompass a sequence that is conserved among HIV isolates and that is hidden in a "canyon" surrounded by hypervariable regions (12, 15) .
The binding of the human immunodeficiency virus envelope glycoprotein gpl20 to the CD4 molecule is the initial step in the viral replicative cycle. This interaction is therefore an important target for therapeutic intervention for the treatment of human immunodeficiency virus infection. We designed an enzyme-linked immunosorbent assay which detects the interaction between recombinant soluble forms of CD4 and gpl60. This assay could be used as an initial screen of libraries of synthetic chemical compounds and natural products.
Human immunodeficiency virus (HIV), the etiologic agent of AIDS, enters target cells after binding of the exterior envelope glycoprotein gp120 to the surface CD4 molecule. CD4 is a 55-kDa glycoprotein which is largely expressed on cells in the immune system. CD4 is a member of the immunoglobulin gene superfamily and consists of four extracellular immunoglobulinlike domains denoted Vi to V4, a transmembrane segment, and a cytoplasmic domain (10, 14) . The interaction between HIV gp120 and CD4 is a welldefined step of the viral replicative cycle. The critical sites for binding on each molecule have been delineated by several different methods, including mutational analyses and studies with monoclonal antibodies (MAbs) and chimeric human and mouse molecules. The high-affinity gp120-binding site on CD4 is localized to a short region of the Vi domain that displays homology with the second complementary determining region of immunoglobulin light chain V domains. Mutational analyses have also demonstrated that the V2 domain of CD4 contributes indirectly to the binding of gp120; mutations in this domain may act by inducing structural changes that affect the conformation of the Vi domain (10, 14) . Indeed, crystallographic analysis of the Vi and V2 domain structure has revealed that Vi and V2 are very closely packed with a beta strand that passes continuously from one domain to another (20, 25) . In contrast, the critical CD4-binding site(s) on gpi20 is not well characterized. Several studies indicate that this site may encompass a sequence that is conserved among HIV isolates and that is hidden in a "canyon" surrounded by hypervariable regions (12, 15) .
Because the interaction of HIV gpl20 with CD4 is the initial step in the viral replicative cycle, it is an important target for therapeutic intervention for the treatment of HIV infection. Several groups have reported the ability of recombinant, soluble forms of the CD4 molecule (sCD4) to inhibit HIV infection in vitro (10) . Phase I clinical trials with sCD4 (Vi to V4) have demonstrated that sCD4 is nontoxic in humans (8, 22, 24 (10) and erythrocytes (6) . These CD4-based chimeric molecules maintain strong in vitro antiviral effects.
In addition to the rationally designed molecules described above, several groups have developed simple and rapid in vitro assays to empirically screen for inhibitors of HIV replication (2, 7, 14, 16, 23) . In order to measure the interaction between HIV and the CD4 receptor, several groups have developed assays which use CD4+ cells and viral particles. These assays measure the potential contribution of other virus and/or cell surface molecules besides gpl20 and CD4 (12, 13) .
In order to precisely measure the interaction between HIV gpl20 and CD4 at the molecular level and to screen for potential inhibitors of this interaction, it is necessary to design a simple assay which measures this interaction in the absence of other cellular, viral, or cell surface molecules. Recently, Moore (18) described an indirect sandwich enzyme-linked immunosorbent assay (ELISA) which measures gp120-CD4 complex formation on microtiter plates precoated with antibodies. We designed direct ELISAs which monitor the interaction of the soluble form of gpl60 (sgp160) with immobilized sCD4 and vice versa. The properties of these ELISAs and their different applications are presented in this report.
MATERIALS AND METHODS
Recombinant molecules. We produced and purified soluble CD4 as described previously (6 (12) (Genetic Systems, Seattle, Wash.); and 160 (a generous gift from B. Krust [11] ). R120c is a rabbit anti-glycoprotein serum raised against the gpl20 C terminus produced in Escherichia coli and was a generous gift of R. Sweet. K582 and K583, and K584 and K585 are sera from rabbits immunized against sCD4 and gpl20, respectively. ELISAs for CD4-gpl60 binding. Ninety-six-well Immulon II and I microtitration plates (Dynatech, Chantilly, Va.) were coated overnight at 4°C with sCD4 and sgpl60, respectively. These first molecules to be immobilized were added to each well as 50 ,ul of a 1-ng/pJ solution diluted in sodium carbonate (0.05 M) buffer (pH 9.6). Wells were then saturated with 100 ,ul of phosphate-buffered saline (PBS) containing 5% bovine serum albumin (BSA) fraction V (Sigma) for 2 h at room temperature. Nonspecific background levels were obtained with noncoated wells saturated under the same conditions. In all ELISAs, three washes with 250 RI of PBS containing 0.05% Tween 20 (Bio-Rad, Richmond, Calif.) per well were done after each incubation. All reagents were diluted in PBS containing 0.1% BSA fraction V and 0.05% Tween 20 (PBTw) and were added at a volume of 50 pI per well. For sgpl6O-sCD4 binding assays, increasing amounts of sgpl60 or sCD4 (referred to here as ligands) were added to sCD4-or sgpl60-coated wells overnight at 4°C. The detection of bound ligand was done by the addition to each well of 50 ,ul of the indicated dilutions of specific antiglycoprotein or anti-CD4 MAbs or rabbit polyclonal antibodies for 2 h at room temperature. Bound antibodies were revealed by the addition a 1:1,000 dilution of peroxidaseconjugated rabbit immunoglobulins to mouse immunoglobulins or peroxidase-conjugated swine immunoglobulins to rabbit immunoglobulins for 2 h at room temperature. In all ELISAs, the enzymatic revelation was done by the addition to each well of 100 RI1 of ortho-phenylenediamine (Diagnostics Pasteur, Marnes La Coquette, France) in substrate buffer for 30 min at room temperature in the dark, according to the instructions of the manufacturer. The reaction was then stopped by the addition to each well of 50 p.l of 4 N H2SO4 in the dark. Optical densities (ODs) were then examined and the results were expressed as the means of the change in ODs (AOD = OD492/OD620 on coated wells -OD492/OD620 on noncoated wells saturated with PBS containing 5% BSA fraction V [OD492 and OD620 are ODs at 492 and 620 nm, respectively]). Each experimental point was determined in duplicate, and all experiments were repeated at least twice.
Inhibition assays. The ligand was preincubated for 2 h at room temperature with adequate dilutions of potential inhibitors on wells presaturated with PB. The mixture (50 RI) was then transferred to antigen-coated wells, and the binding assay was then performed as described above. We also tested the inhibition of the CD4-gpl60 interaction by anti-CD4 MAbs. Wells were preincubated with increasing amounts of MAbs for 2 h at room temperature. OKT4 and IOT8 (500 ng per well) were used as negative controls.
Inhibition of the binding of heat-inactivated HIV particles to CEM13 cells. Binding of HIV to CD4-bearing CEM13 cells was performed as described previously (14) . Briefly, 0.5 x 106 cells were incubated for 1 h at 37°C with 100 ,lI of PBS containing 0.5% BSA, 0.05% NaN3, and 1 ,ug of heatinactivated purified HIV-1-bru that was previously preincubated for 1 h at 37°C with increasing amounts of the inhibitors. Cells were then incubated with 100 plA of a 1:100 dilution of MAb 110-4 for 30 min at 4°C. Bound MAbs were revealed with 100 RI of a 1:25 dilution of biotinylated sheep anti-mouse immunoglobulins (Amersham, Buckinghamshire, England). Finally, 100 p.1 of a 1:1,600 dilution of phycoerythrin-conjugated streptavidin (Southern Biotechnology Associate, Birmingham, Ala.) was added to cells for 30 min at 4°C. Extensive washes were made between each incubation, and cells were finally resuspended in 500 pul of PBS containing 1% paraformaldehyde (Sigma). Immunofluorescence was determined by flow cytometry by using a FACS analyzer (Becton Dickinson).
Inhibition of HIV infection in MT2 cells. A total of 5 x 106 cells were infected with 50 50% tissue culture infective doses of HIV-1-bru, which was preincubated for 1 h at 4°C with increasing amounts of the inhibitor in 1 ml of culture medium, which was RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, 1% L-glutamine, and 1% penicillin-streptomycin-neomycin, for 2 h at 37°C. Cells were then washed twice with 5 ml of RPMI 1640 medium, resuspended in culture medium containing similar dilutions of the inhibitor, and distributed in 96-well culture microplates. Each well contained 25,000 cells in 200 ,ul. Each infection point was determined in octaplicate. At days 3, 6, and 9, 100 pI of cell supernatant was removed from each well and was preserved at -80°C for further analysis. This medium was replaced by the same volume of fresh culture medium containing the same concentrations of inhibitor. At day 9, cell viability was assessed by a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazollum bromide colorimetric method, and stocked supernatants were analyzed for HIV viral antigenemia (23) .
RESULTS
Development of an CD4-gpl6O ELISA using recombinant proteins. We designed our ELISAs as direct assays in which either sCD4 or sgpl60 was coated onto microtiter plates. We first determined the efficiencies of coating of sCD4 and gpl60 to plastic microtiter wells, and then we determined their subsequent immunoreactivities. For detection of immobilized sCD4, we used Leu3a and OKT4A, two MAbs directed against epitopes located in the Vl domain of CD4, close to the gpl20-binding site, and inhibitory for HIV infection in vitro. We also used the MAb OKT4, which recognizes the V3 and V4 domains of CD4, a region which is not involved in the binding of CD4 to gpl20 (10) . Figure 1A shows that immobilized sCD4 is efficiently recognized by both Leu3a and OKT4A and is detected to a lesser extent by OKT4. No background reactivity could be measured with an irrelevant anti-CD8 MAb. Immobilized sCD4 was also efficiently recognized by polyclonal antisera raised in two rabbits immunized with sCD4. On the other hand, immobilized sgpl60 could be detected by one MAb (MAb 110-4) and all three rabbit anti-glycoprotein polyclonal antisera, but not by control preimmune sera (Fig. 1B) .
We then analyzed the binding of sgpl60 to immobilized sCD4. The highest AOD values measuring captured sgpl60 were obtained with MAb 110-4 and R120c antisera. In addition, we analyzed the ability of immobilized sgpl60 to capture sCD4. Of the anti-CD4 antibodies, MAb OKT4 and the rabbit polyclonal antiserum K582 yielded the most efficient detection system (data not shown).
Dose dependence, saturability, and specifity of the CD4-gpl60 ELISA. As shown in Fig. 1C, sgpl60 binds to immobilized sCD4 in a dose-dependent manner. Half-maximum binding was reached at a sgpl60 concentration of approximately 3 nM, in accordance with the affinity constant of the CD4-gp120 interaction determined by others (10, 15, 18) . Likewise, the binding of sCD4 to immobilized sgpl60 is also dose dependent (data not shown). Inhibition with increasing amounts of sCD4 resulted in the dose-dependent inhibition of binding of sgpl60 to immobilized sCD4. The 50% inhibitory concentration (IC50) corresponded to a concentration of the inhibitor in an approximately molar ratio with the ligand (Table 1 ). This assay demonstrated good reproducibility. The variations among duplicate determinations within each experiment were very low, and the variations between experimental points repeated in independent experiments were comparable to those commonly observed in commercial ELISAs. However, the absolute AOD values obtained with sgpl60 from different batches may differ significantly, although this does not affect the overall performance of the ELISA since the IC50s and IC90s were comparable (Table 1) .
Similarly, MAbs Leu3a and OKT4A, but not MAbs OKT4 or IOT8, inhibited the binding of sgpl60 to immobilized sCD4 in a dose-dependent fashion (Fig. 1D) . These results demonstrate that the same antibodies that inhibit HIV binding to target cells also inhibit the HIV gpl60-CD4 interaction in our ELISA. Surprisingly, the binding of sCD4 to immobilized sgpl60 was not inhibited by increasing amounts of sgpl60 in the solution phase, and Leu3a and OKT4A inhibited sCD4 binding to sgpl60 at concentrations 100-fold higher than those in the previous assay (data not shown). CD4-gpl60 ELISA in comparison with other assays. Once an inhibitor was identified in the ELISA described here, its inhibitory activity had to be confirmed in complementary assays. One assay measured the multivalent interaction between an HIV particle and a CD4+ target cell by detecting the binding of heat-inactivated HIV-1 particles to CEM13 cells with an anti-gp120 MAb (14) . sCD4 inhibited this interaction in a dose-dependent manner (Table 1; Fig. 2B ). The second assay measured the ability of potential inhibitors to block infection of MT2 cells with HIV by measuring cell viability and viral antigenemia in culture supernatants of both infected and uninfected cells. The two assays gave similar results (data not shown). As in the previous assays, sCD4 inhibited HIV infection of MT2 cells in a dosedependent manner (Table 1 ; Fig. 2C ).
Application to the screening of potential HIV inhibitors. The reference inhibitor sCD4 inhibited the CD4-gpl60 interaction in the ELISA, heat-inactivated HIV binding to CEM13 cells, and HIV infection of MT2 cells (Table 1) . We also demonstrated that the Vi domain of CD4 produced in bacteria efficiently inhibits the ELISA (data not shown), but seven short CD4-based peptides, which overlapped the putative gpl20-binding site, all failed to demonstrate any inhibitory activity in the ELISA, even when they were used at 1,000-fold higher concentrations than the IC50 obtained with sCD4 (data not shown). In addition, we tested heparin (molecular weight, 23,000), dextran sulfate (molecular weight, 5,000), dextran (molecular weight, 77,800), pentosan polysulfate, chondroitin sulfate A, and chondroitin sulfate B in the ELISA. Only dextran sulfate (molecular weight, 5,000) and pentosan polysulfate demonstrated inhibitory activity in the ELISA (Fig. 2A ) at the highest dose tested (10 ,uM) . None of these compounds significantly inhibited the binding of HIV particles to CEM13 cells (Fig. 2B) . In an HIV infectivity assay of MT2 cells (Fig. 2C) , we observed an anti-HIV activity of the two sulfated polysaccharides at concentrations of 10 puM.
Determination of sCD4 in animal sera. Given the dosedependent binding of sCD4 to immobilized sgpl60, we examined the binding of known amounts of sCD4 diluted in rabbit serum and detected by MAb OKT4. As shown in Fig.  3 , the efficiency of sCD4 capture was identical to that obtained with sCD4 diluted in PBTw, and very low concentrations of sCD4 (0.1 nM [2 ng/50 pul]) could be detected. The binding curve reached a plateau at 25 ng of sCD4 per 50 pul.
For AODs in this range, the sample could be diluted to determine its concentration more precisely.
DISCUSSION
The interaction of HIV gpl20 with the CD4 receptor is an important target for the development of anti-HIV therapeutic agents. Several groups of investigators have generated sCD4 as well as several sCD4 derivatives that inhibit this interaction. In addition to this rational therapeutic design, it Moore (18) , who used an indirect ELISA in which sCD4 is bound to plates precoated with an anti-CD4 MAb. However, it appears that our ELISA is more sensitive and saves time and reagents involved in the indirect immobilization procedure.
The ELISA system is well suited for screening of inhibitors of the interaction of HIV gpl60 with CD4 in an automated, high-throughput mode. Several reference CD4-based molecules demonstrated good inhibition in our ELISA and were able to inhibit the binding of HIV particles to target cells and subsequent HIV infection. Nevertheless, it is possible that potential inhibitors might be effective in the ELISA but not in the other assays. For example, an inhibitor that weakly blocked the monovalent interaction between HIV sgpl60 and sCD4 might not be effective in inhibiting the highly multivalent interaction which occurs when an HIV particle binds to a target cell. In this regard, we have demonstrated that sulfated dextran and sulfated pentosan inhibit the interaction between sgpl60 and sCD4 in the ELISA, with an IC50 at least 4 log units higher than that obtained with sCD4. However, we failed to detect any significant inhibition of the binding of HIV particles to CD4+ target cells with these compounds. These data are in agreement with most previously published observations (19, 21, 26) , which indicated that the antiviral effects of these compounds, which were demonstrated in HIV-infected cultures, were not mainly due to the inhibition of CD4-gpl2O binding. Interestingly, it has recently been demonstrated that dextran sulfate is an inhibitor of HIV reverse transcriptase (17) .
Finally, we demonstrated that our CD4-gpl6O ELISA can be performed in pure rabbit sera, indicating that it will be suitable to monitor the concentration of any inhibitor of this interaction in serum. Recently, we used this ELISA to determine the half-life in serum of a CD4-based chimeric molecule injected into rabbits. The difficulties encountered with the use of sCD4 as a therapeutic agent in humans necessitates the development of new CD4-based compounds with increased antiviral properties as well as compounds identified through empirical drug screening. In this respect, it has recently been shown that fresh isolates obtained from HIV-infected patients are more resistant to neutralization by the soluble form of T4 (4). However, there is recent evidence that this resistance is not mainly due to a decrease in CD4-recombinant gpl20 binding affinity (1, 3) . When the recombinant glycoproteins of primary isolates become available, it would be of interest to examine their behaviors in our assay.
